https://scholars.lib.ntu.edu.tw/handle/123456789/627610
標題: | Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan | 作者: | YU-YUN SHAO Wang, Shen-Yung Lin, Shi-Ming Chen, Kuan-Yang Tseng, Jeng-Hwei MING-CHIH HO Lee, Rheun-Chuan PO-CHIN LIANG Liao, Li-Ying KAI-WEN HUANG Hu, Jui-Ting JA-DER LIANG Kee, Kwong-Ming Lin, Chih-Lin Wang, Chung-Kwe Lu, Sheng-Nan Wang, Jing-Houng Lee, Wei-Chen CHIEN-HUNG CHEN CHUN-JEN LIU Huang, Yi-Hsiang Wang, Chia-Chi Wang, Tsang-En Chuang, Po-Heng Dai, Chia-Yen CHIUN HSU Chen, San-Chi Hsieh, Chia-Hsun |
關鍵字: | Diagnosis; Guideline; Hepatocellular carcinoma; Surveillance; Systemic treatment | 公開日期: | 四月-2021 | 出版社: | ELSEVIER TAIWAN | 卷: | 120 | 期: | 4 | 起(迄)頁: | 1051 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid-enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627610 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2020.10.031 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。